Table 2.
Clinical trials conducted in dry AMD.
| Name of the Study | Date | Investigated Drug | Number of Participants | Results | Ocular Adverse Events |
|---|---|---|---|---|---|
| OAKS [27] | 2018–2020 (24 months) |
pegcetacoplan | 637 | % GA reduction in treated vs. sham Monthly: 21% (p = 0.0528) |
1.6% |
| DERBY [27] | 2018–2020 (24 months) |
pegcetacoplan | 621 | % GA reduction in treated vs. sham Monthly: 12% (p = 0.0528) |
1.3% |
| GATHER1 [28] | 2016–2019 (18 months) |
avacincaptad pegol |
286 | % GA reduction in treated vs. sham 2 mg: 27.4% (p = 0.0072) 4 mg: 27.8% (p = 0.0051) |
≥2% |
| GATHER2 [29] | 2020–2021 (12 months) |
avacincaptad pegol |
448 | % GA reduction in treated vs. sham 2 mg:14% (p = 0.0064) |
49% |
| BEACON [30] | 2014–2018 (30 months) |
brimonidine | 310 | % GA reduction in treated vs. sham 400 μg: 10% (p = 0.033) |
62.3% |